NEDA-state, psychological symptoms and quality of life are stable in natalizumab-treated multiple sclerosis patients: An up to 6-years long follow-up study

NEDA-state, psychological symptoms and quality of life are stable in natalizumab-treated multiple sclerosis patients: An up to 6-years long follow-up study

Introduction: Natalizumab (NAT), a highly effective disease modifying therapy (DMT) in relapsing-remitting multiple sclerosis (RRMS), was approved for clinical use in Hungary on February 1, 2010. In this study we aimed to assess its effectiveness in view of the concept of “No Evidence of Disease Act...

Full description

Bibliographic Details
Main Authors: Dániel Sandi, Zsófia Kokas, Zsigmond Tamás Kincses, Judit Füvesi, Zsanett Fricska-Nagy, Erika Vörös, Tamás Biernacki, László Vécsei, Péter Klivényi, Krisztina Bencsik
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:Heliyon
Subjects:
Natalizumab
Multiple sclerosis
NEDA-3
Limb function
Pathopsychological symptoms
Quality of life
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024155673

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024155673

Similar Items